Autonomix Seeks Approval for Another Reverse Split and 750K-Share Equity Plan Expansion
AMIX sits 84% above its 52-week low of $2.44.
Summary
Autonomix Medical's preliminary proxy seeks approval for a new reverse stock split (1-for-2 to 1-for-25) and a 750,000-share expansion of its equity incentive plan, reflecting ongoing Nasdaq listing pressure and cash conservation needs.
Key Events · Corporate Governance and Compliance · AMIX
-
New Reverse Split Authorization Sought
Proposal 3 asks stockholders to approve a reverse split between 1-for-2 and 1-for-25, giving the Board discretion to implement it within one year. This follows the 1-for-21 split completed June 24, 2026, which did not durably maintain the $1 minimum bid price.
-
Equity Plan Expansion of 750K Shares
Proposal 4 would increase the 2023 Equity Incentive Plan reserve from 135,354 to 885,354 shares, creating a 22.9% overhang. The plan also has an evergreen provision adding 5% of outstanding shares annually through 2033.
-
Listing Pressure Continues
The proxy states the stock trades near the $1 minimum and that the reverse split is intended to reduce delisting risk. The company previously regained compliance in July 2026 but faces a new $5M minimum market value rule risk disclosed in the August 2026 10-Q.
-
Annual Meeting Set for October 29, 2026
Record date is September 8, 2026, with 1,828,505 shares outstanding. Proposals include electing five directors, ratifying Forvis Mazars as auditor, the reverse split, and the equity plan amendment.
Analysis · AMIX · Industrial Applications And Services
Autonomix Medical is asking shareholders to authorize a second reverse stock split in just over a year — a 1-for-2 to 1-for-25 range — after the 1-for-21 split completed in June 2026 failed to durably lift the stock above Nasdaq's $1 minimum. The company also wants to expand its equity incentive plan by 750,000 shares, creating a 22.9% overhang. Both moves signal continued listing pressure and a reliance on equity compensation to conserve cash, with the company's cash runway only extending into Q1 2027.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMIX was trading at $4.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $2.44 to $32.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.